Summary:
You are invited to take part in this research study because you have kidney disease with protein in your urine (proteinuric chronic kidney disease [CKD]). We are doing this study to learn how effective, tolerable and safe an experimental drug called AZD5718 is in treating participants with proteinuric CKD.
Treatments that reduce the amount of albumin in urine have improved outcomes for patients with CKD. This study is being conducted to assess whether AZD5718 can reduce the amount of albumin in the urine of participants with proteinuric CKD. The study will also determine the most effective dose of AZD5718. The amount of AZD5718 in the blood will be measured to study the rates of absorption into the bloodstream and clearance from the body.
Qualified Participants Must:
• Diagnosis of Chronic Kidney Disease
•
Other criteria will apply. Details will be provided.
Qualified Participants May Receive:
You will be reimbursed for travel and related expenses up to the amount of $60 per study
visit.